These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17435629)

  • 1. Bupropion normalizes cognitive performance in patients with depression.
    Gualtieri CT; Johnson LG
    MedGenMed; 2007 Jan; 9(1):22. PubMed ID: 17435629
    [No Abstract]   [Full Text] [Related]  

  • 2. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
    Herrera-Guzmán I; Gudayol-Ferré E; Lira-Mandujano J; Herrera-Abarca J; Herrera-Guzmán D; Montoya-Pérez K; Guardia-Olmos J
    Psychiatry Res; 2008 Jul; 160(1):72-82. PubMed ID: 18501971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression.
    Jamerson BD; Krishnan KR; Roberts J; Krishen A; Modell JG
    Psychopharmacol Bull; 2003; 37(2):67-78. PubMed ID: 14566216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of bupropion XR in treatment-resistant elderly patients: a case series study.
    Bergman J; Miodownik C; Palatnik A; Lerner V
    Clin Neuropharmacol; 2011; 34(1):17-20. PubMed ID: 21206361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
    Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode.
    Schönfeldt-Lecuona C; Connemann BJ; Wolf RC; Braun M; Freudenmann RW
    Pharmacopsychiatry; 2006 Jul; 39(4):152-4. PubMed ID: 16871471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depressive symptoms, major depressive episode and cognition in the elderly: the three-city study.
    Godin O; Dufouil C; Ritchie K; Dartigues JF; Tzourio C; Pérès K; Artero S; Alpérovitch A
    Neuroepidemiology; 2007; 28(2):101-8. PubMed ID: 17409771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.
    Hewett K; Chrzanowski W; Jokinen R; Felgentreff R; Shrivastava RK; Gee MD; Wightman DS; O'Leary MC; Millen LS; Leon MC; Briggs MA; Krishen A; Modell JG
    J Psychopharmacol; 2010 Apr; 24(4):521-9. PubMed ID: 19164492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Markers of cognitive vulnerability in major depression].
    Sárosi A; Balogh G; Székely A; Sasvári M; Faludi G
    Neuropsychopharmacol Hung; 2007 Dec; 9(4):183-8. PubMed ID: 18510262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does sleep disturbance mediate neuropsychological functioning in older people with depression?
    Naismith SL; Norrie L; Lewis SJ; Rogers NL; Scott EM; Hickie IB
    J Affect Disord; 2009 Jul; 116(1-2):139-43. PubMed ID: 19128840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive control and brain resources in major depression: an fMRI study using the n-back task.
    Harvey PO; Fossati P; Pochon JB; Levy R; Lebastard G; Lehéricy S; Allilaire JF; Dubois B
    Neuroimage; 2005 Jul; 26(3):860-9. PubMed ID: 15955496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine, cognitive and structural imaging characteristics of women on longterm sickleave with job stress-induced depression.
    Rydmark I; Wahlberg K; Ghatan PH; Modell S; Nygren A; Ingvar M; Asberg M; Heilig M
    Biol Psychiatry; 2006 Oct; 60(8):867-73. PubMed ID: 16934773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of aromatherapy massage on mild depression: a pilot study.
    Okamoto A; Kuriyama H; Watanabe S; Aihara Y; Tadai T; Imanishi J; Fukui K
    Psychiatry Clin Neurosci; 2005 Jun; 59(3):363. PubMed ID: 15896234
    [No Abstract]   [Full Text] [Related]  

  • 15. Bupropion in the management of apathy.
    Corcoran C; Wong ML; O'Keane V
    J Psychopharmacol; 2004 Mar; 18(1):133-5. PubMed ID: 15107198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive performance and subjective complaints before and after remission of major depression.
    Lahr D; Beblo T; Hartje W
    Cogn Neuropsychiatry; 2007 Jan; 12(1):25-45. PubMed ID: 17162445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nature and determinants of neuropsychological functioning in late-life depression.
    Butters MA; Whyte EM; Nebes RD; Begley AE; Dew MA; Mulsant BH; Zmuda MD; Bhalla R; Meltzer CC; Pollock BG; Reynolds CF; Becker JT
    Arch Gen Psychiatry; 2004 Jun; 61(6):587-95. PubMed ID: 15184238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of psychiatric and medical comorbidity on cognitive function in depression.
    Baune BT; McAfoose J; Leach G; Quirk F; Mitchell D
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):392-400. PubMed ID: 19566772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression.
    Cox LS; Patten CA; Niaura RS; Decker PA; Rigotti N; Sachs DP; Buist AS; Hurt RD
    J Gen Intern Med; 2004 Aug; 19(8):828-34. PubMed ID: 15242467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
    Thase ME; Clayton AH; Haight BR; Thompson AH; Modell JG; Johnston JA
    J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.